HALO241220P35000
- 0.20
- +0.03+17.65%
Halozyme Therapeutics Newsroom
H.C. Wainwright Maintains Halozyme Therapeutics(HALO.US) With Buy Rating, Maintains Target Price $68
Halozyme Therapeutics Price Target Maintained With a $68.00/Share by HC Wainwright & Co.
Halozyme Therapeutics Analyst Ratings
JMP Securities Maintains Halozyme Therapeutics(HALO.US) With Buy Rating, Maintains Target Price $73
Halozyme Therapeutics Analyst Ratings
H.C. Wainwright Maintains Halozyme Therapeutics(HALO.US) With Buy Rating, Maintains Target Price $68
JMP Securities Maintains Halozyme Therapeutics(HALO.US) With Buy Rating, Maintains Target Price $73
Wells Fargo Maintains Halozyme Therapeutics(HALO.US) With Hold Rating, Maintains Target Price $62
J.P. Morgan Maintains Halozyme Therapeutics(HALO.US) With Hold Rating, Announces Target Price $54
JMP Securities Maintains Halozyme Therapeutics(HALO.US) With Buy Rating, Maintains Target Price $73
Halozyme Therapeutics Analyst Ratings
Piper Sandler Maintains Neutral on Halozyme Therapeutics, Raises Price Target to $52
Halozyme (HALO) Receives a Hold From Piper Sandler
TD Cowen Maintains Halozyme Therapeutics(HALO.US) With Buy Rating, Maintains Target Price $70
Halozyme Therapeutics Is Maintained at Market Outperform by JMP Securities
H.C. Wainwright Maintains Halozyme Therapeutics(HALO.US) With Buy Rating, Raises Target Price to $68
JMP Securities Maintains Halozyme Therapeutics(HALO.US) With Buy Rating, Raises Target Price to $73
TD Cowen Maintains Halozyme Therapeutics(HALO.US) With Buy Rating, Maintains Target Price $70
Leerink Partners Maintains Halozyme Therapeutics(HALO.US) With Hold Rating, Announces Target Price $136
A Quick Look at Today's Ratings for Halozyme Therapeutics(HALO.US), With a Forecast Between $62 to $72